Italian contract research organisation (CRO) Pierrel has acquired Encorium’s US clinical trial operations in a $2.7m (€1.9m) deal that could provide a much needed lifeline for the troubled group.
India’s Central Drug Standard Control Organisation (CDSCO) wants CROs and trial sponsors to justify and document the increasingly large quantities of drugs and APIs they import for clinical trials.
Andrew Baker, the chairman and CEO of Life Sciences Research, an East Millstone, New Jersey, contract research organization, has obtained "a definitive agreement" to acquire the firm for $8.50 per share in cash.
The US National Cancer Institute (NCI) will provide specialist trial group Cancer Research for the Ozarks (CRO) with a $4.2m grant to support its clinical programme.
US software company Velos hopes its new “software as a service” (SaaS) internet offering will attract CROs and Pharma firms seeking low-cost trial management solutions.
US CRO PPD has laid off around 80 people at its HQ in Wilmington, North Carolina and may cut another 200 jobs from its North American workforce, according to local media reports.
South-Africa based ACRO is aiming at building partnerships across its home continent, according to its MD who told Outsourcing-Pharma of its ambition to have more local people performing research.
The number of CROs operating in the United Arab Emirates (UAE) is set to rise, according to an expert on the region, as companies are attracted by the cost effectiveness and presence of big pharma.
Medidata has followed up its successful IPO by inking a deal with Roche, which is reported to be pulling out of PhRMA and the ABPI, to provide the Swiss pharma with an enterprise-wide electronic EDC system.
Teva plans to acquire oncology drugs that fail late-stage clinical trials and collaborate with Optimata to "efficiently rescue" the therapeutics and gain regulatory approval.
US CRO PPD has abandoned plans to move into a 40,000 sq ft office building in North Carolina’s Kannapolis biotech complex due to slower than expected development.
Chinese CROs Sundia MediTech, Huiyuan Biotechnology and Frontage Laboratories are the first companies grated express customs clearance privileges under new government pro outsourcing rules.
Merz is hoping to further its Alzheimer’s research by licensing DiaGenic’s biomarkers for a transitional stage of disease, which is “very important” for stratification of clinical trials.
Perceptive Informatics has launched an integrated eClinical suite, which it believes streamlines workflow and allows users to access data across multiple technologies throughout trials.
Synteract will open an office in Prague in the Czech Republic, joining the growing number of CROs to offer sponsors access to treatment naive populations in Central and Eastern Europe (CEE).
Medidata has launched a programme to encourage interoperability and data sharing across clinical trial technologies, which should help cope with the complexity of modern research.
Excel Life Sciences (ELS) and PFC Pharma Focus have launched a joint venture in India in response to growing client demand for services in the country delivered by established and proven providers.
Physicians say a lack of information about candidate drugs often prevents them referring patients for clinical trials, according to a new survey by sector analysts CenterWatch.
Icon has entered into a collaboration with the Central Manchester University Hospitals Foundation (CMFT) to establish a purpose built translational medicine facility in the UK.
UK CRO Quintiles Transnational has set up an office in Accra, Ghana in a move it claims allows it to recruit trial participants from sub-Saharan Africa’s estimated 760m residents.
US group DZS Software Solutions says its new web ClinPlus CTMS technology will help sponsors and CROs ensure that trial procedures are being followed and eliminate redundant study management systems.
US genomic services specialist Cogenics has launched a new DMET analysis service that it believes will improve patient genotyping during clinical trials, helping drug industry sponsors target the development of new products and reduce costs.
Canadian CRO MDS Pharma Services (MDS) is to sell its Phase II-IV trial business to US counterpart INC Research for $50m (€35m) and focus on providing discovery and early clinical development services.
US Patient recruitment specialist BBK Worldwide has set up a unit in Osaka, Japan to improve enrolment rates for studies in the country and help local pharma and biotech firms cut costs.
US CRO Ockham Development group will start providing customers with data capture and analysis solutions developed by etrials under a new, five year licensing agreement.
Biotechs use smaller CROs as much as larger service providers and regard patient recruitment speed as by far the most important characteristic, according to a report.
UK CRO Quotient Bioresearch has bought a clinical research facility in Edinburgh, Scotland, which in conjunction with an existing unit in Nottingham, England will serve as a base for its new Quotient Clinical unit.
The increasingly global clinical trial sector demands more effective ethical and regulatory scrutiny according to a study published in the latest edition of the New England Journal of Medicine (NEJM).
CRO Encorium has unveiled plans to sell both its US business and its Finnish subsidiary Encorium Oy just weeks after posting a gloomy set of Q1 financials dominated by a 15 per cent drop in net revenues.
Definitive FDA guidance on adaptive trials cannot come soon enough for the pharmaceutical and biotech sectors, according to Perceptive Informatics (PI).
CRO Eurotrials has brought in US business consultant AmeriStart to publicise and sell its trial services to pharmaceutical and biotech firms in North America.
US contract research organisation (CRO) Encorium has reported $2m in new and repeat business deals on the same day it posted gloomy Q4 figures and cited the "drop in demand" refrain heard across the trial sector.
Icon’s net new business fell by 28 per cent in Q1 but the overall picture was better, with operating profits rising by 25 per cent and a US acquisition expanding its Phase I capacity.
19 out of 21 pharmaceutical companies surveyed by Cutting Edge Information ranked a contract research organisation’s ability to hit trial deadlines as either “extremely important” or very “important,” making it the top quality identified by respondents.
Parexel posted a doubling in cancellations in Q3 of its fiscal year, with profits remaining flat as an eight per cent boost in service revenue was offset by higher operating expenses.
German CRO Clinicalprojects International (CPI) will begin providing its customers with the TrialMaster EDC solution though a deal with developer OmniComm.
Coast IRB has decided to close after a probe by US Government Accountability Office (GAO) and subsequent FDA warning letter resulted in the loss of “several key customers”.
US firm Kendle is the latest CRO to revise its forecast and blame “unprecedented biopharmaceutical industry conditions,” which are fast becoming an industry catchphrase, for its Q1 woes.
PPD’s revenues dipped in Q1 as the company was hit by contract cancellations totaling $215m (€166m), which included a $77m deal with a large biotech for a multinational clinical trial.
Following calls for increased transparency PhRMA has published its new clinical trial principles, which contain revisions relating to registration, authors and sponsor disclosure.
Indian CRO Siro ClinPharm is teaming up with New Jersey based pharma services firm Advanced Clinical Trial Solutions (ACT) to strengthen its position in the US cancer trial sector.